Popular search terms:
Search Results
31 results found-
Here you will find the range of pharmaceutical products that we offer in the UK for immunodeficiency, haemophilia, and other rare and serious diseases.
https://www.cslbehring.co.uk/products/product-range -
CSL Behring is a specialty biotherapeutics company that is committed to treating people with rare and serious medical conditions.
https://www.cslbehring.co.uk/products -
CSL Behring is a global leader in the plasma protein biotherapies industry. We research, develop, manufacture and market biotherapies, which are used to treat serious and rare conditions.
https://www.cslbehring.co.uk/our-company -
CSL Behring is a global specialty biopharmaceutical company which aims to identify, develop and commercialise important, new, biotherapeutic products that help to prevent or treat serious medical conditions.
https://www.cslbehring.co.uk/research-and-development -
CSL Behring biotherapies are manufactured in state-of-the-art facilities under stringent, controlled conditions.
https://www.cslbehring.co.uk/products/regulatory-compliance -
CSL Behring is committed to improving the quality of life for people with rare and serious diseases worldwide.
https://www.cslbehring.co.uk/terms-of-use -
CSL Behring is committed to support Investigator-Initiated Studies (IIS) that advance medical and scientific knowledge of CSL Behring products and the diseases they are designed to treat.
https://www.cslbehring.co.uk/research-and-development/iis -
CSL Behring is committed to improving the quality of life for people with rare and serious diseases worldwide.
https://www.cslbehring.co.uk/careers/roles-at-csl-behring-uk -
CSL Behring is committed to improving the quality of life for people with rare and serious diseases worldwide.
https://www.cslbehring.co.uk/home -
Product Name Hizentra 200 mg/ml solution for subcutaneous injection Active Ingredient Human normal immunoglobulin Composition One ml contains:
https://www.cslbehring.co.uk/-/media/cslb-uk/product-information/update-april-2023/product-info---hizentra-inc-pfs-update-april-2023.pdf